Singapore markets closed

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.900.00 (0.00%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.90
Open13.90
Bid0.00 x 0
Ask0.00 x 0
Day's range13.90 - 13.90
52-week range8.65 - 18.00
Volume13
Avg. volume132
Market cap405.482M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-0.33
Earnings date23 May 2024
Forward dividend & yield0.23 (1.65%)
Ex-dividend date29 Jun 2023
1y target estN/A
  • GlobeNewswire

    IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US

    Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE1 compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the center wil

  • GlobeNewswire

    Iba – Transparency Notification

    Louvain-la-Neuve, Belgium, April 11, 2024, 6pm Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007, on disclosure of major holdings, further to the notification received on April 9, 2024. In its notification, Vallcara Limited indicated that following an acquisition, its to

  • GlobeNewswire

    IBA Reports Full Year 2023 Results

    GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1% REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING MEDIUM TERM GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 21 March 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year. (EUR 000)FY 2023FY 2022VarianceVariance %Total Net Sales428 717361 27067 44718.7% Proton Therapy229 065 218 76110 3044.7% Other Accelerator